Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria
An Open Label Dose Adjusted Phase II Trial of the Oral Farnesyltransferase Inhibitor (FTI) Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies
Sponsor: Monica E. Kleinman
This PHASE2 trial investigates Hutchinson-Gilford Syndrome and Progeria and is currently completed. Monica E. Kleinman leads this study, which shows 11 recorded versions since 2007 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jul 2019 — Sep 2020 [monthly]
Completed PHASE2
-
Jun 2018 — Jul 2019 [monthly]
Completed PHASE2
-
May 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Jul 2017 — May 2018 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Feb 2017 — Jul 2017 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2
First recorded
May 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Monica E. Kleinman
- Schering-Plough
For direct contact, visit the study record on ClinicalTrials.gov .